The effect of perendoscopic sclerosing agent injection in Forrest's II XXXX -- a pilot study from Turkey.

@entity1 @entity1066 @entity204 @entity1943 @entity5324 @entity360 @entity4546
BACKGROUND: We aimed to clarify the outcome of perendoscopic prophylactic injection of sclerosing agent in Forrest's II @entity1066 . MATERIAL/METHODS: @entity1 with @entity360 in last 6 hours were performed emergency endoscopy and were enrolled. The @entity1 in group-1 were performed prophylactic injection therapy with 1% @entity5324 and then given medical treatment with intravenous 40 mg @entity4546 twice a day and @entity1943 infusion at the dose of 6 mg/day during 3 days. Group-2 @entity1 were only given medical treatment with same agents and at same doses without having any perendoscopic therapy. RESULTS: There were 32 @entity1 in group-1 and 20 in group-2. In emergency endoscopy, 20 (62.5%) @entity1 had IIa @entity1066 and 12 (37.5%) @entity1 had IIb @entity1066 in group-1. These @entity1 underwent prophylactic perendoscopic hemostasis by 1% @entity5324 in addition to medical treatment. Early rebleeding occurred in 9 (28.1%) @entity1 of group-1 and 3 (15%) in group-2 (p<0.001). At the endoscopic control after 48 hours 13 (40.6%) @entity1 in the group-1 and 15 (75%) @entity1 in group-2 showed improved local ulcer stigmata (p<0.001). The numbers of blood units transfused were lower in the group-2 (p=0.002). The hospital stay was longer in group-1 (p=0.01). In the group-1, more endoscopic intervention was needed. Any @entity204 and the need for surgical intervention did not occurred in any groups. CONCLUSIONS: According to our results; the indication of perendoscopic prophylactic injection of sclerosing agent in non-bleeding @entity1066 with high risk of rebleeding must be reviewed by large population based, prospective, randomized trials.
